Vimarsana
Biggest News Aggregation in the World

Page 4 - William Bonello News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from William Bonello. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In William Bonello Today - Breaking & Trending Today

NeoGenomics, Inc. Forecasted to Earn Q1 2022 Earnings of ($0.31) Per Share (NASDAQ:NEO) - Vimarsana News

NeoGenomics, Inc. Forecasted to Earn Q1 2022 Earnings of ($0.31) Per Share (NASDAQ:NEO)

NeoGenomics, Inc. (NASDAQ:NEO – Get Rating) – Research analysts at SVB Leerink cut their Q1 2022 EPS estimates for shares of NeoGenomics in a note issued to investors on Monday, March 28th. SVB Leerink analyst P. Souda now anticipates that the medical research company will earn ($0.31) per share for the quarter, down from their […]

NeoGenomics (NASDAQ:NEO) Sees Unusually-High Trading Volume - Vimarsana News

NeoGenomics (NASDAQ:NEO) Sees Unusually-High Trading Volume

Shares of NeoGenomics, Inc. (NASDAQ:NEO – Get Rating) saw an uptick in trading volume on Wednesday . 86,674 shares changed hands during trading, a decline of 93% from the previous session’s volume of 1,174,509 shares.The stock last traded at $12.88 and had previously closed at $12.49. A number of research firms recently commented on NEO. […]

NeoGenomics (NASDAQ:NEO) Downgraded to "Equal Weight" at Stephens - Vimarsana News

NeoGenomics (NASDAQ:NEO) Downgraded to "Equal Weight" at Stephens

Stephens lowered shares of NeoGenomics (NASDAQ:NEO – Get Rating) from an overweight rating to an equal weight rating in a research note issued to investors on Tuesday, Marketbeat.com reports. Stephens currently has $16.00 target price on the medical research company’s stock, down from their prior target price of $34.00. A number of other equities research […]

NeoGenomics (NASDAQ:NEO) Price Target Cut to $20.00 by Analysts at SVB Leerink - Vimarsana News

NeoGenomics (NASDAQ:NEO) Price Target Cut to $20.00 by Analysts at SVB Leerink

NeoGenomics (NASDAQ:NEO – Get Rating) had its price objective lowered by SVB Leerink from $45.00 to $20.00 in a research report released on Tuesday, The Fly reports. The firm currently has an outperform rating on the medical research company’s stock. Several other equities research analysts have also weighed in on the stock. Raymond James cut […]

NeoGenomics in Fort Myers seeks new CEO after disappointing quarter - Vimarsana News

NeoGenomics in Fort Myers seeks new CEO after disappointing quarter

Fort Myers-based cancer-focused testing and research lab NeoGenomics announced Mark Mallon, who had been CEO for less than a year, has stepped down.